An Examination of Infants' Microbiome, Nutrition, and Development Study.
NCT ID: NCT03229863
Last Updated: 2025-12-05
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
NA
Total Enrollment
102 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-04-18
Study Completion Date
2027-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is examining the relationship between infant nutrition, gut health, and development. The fecal microbiota changes and develops, in large part due to the food that infants eat. These changes are important for many aspects of development. This study is designed to examine how the fecal microbiota changes when exclusively breastfed infants are first introduced to solid food, and how changes of the fecal microbiota are related to other aspects of development.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Development of Preterm Infant Gut Microbiome
NCT03552952
Premature Infants
UNKNOWN
First Complementary Foods and the Infant Gastrointestinal Microbiota
NCT05492253
Healthy Participants
Infants
Gastrointestinal Microbiota
COMPLETED
NA
Gastrointestinal Tract Microbiome in Healthy Term Infants Receiving Mother'S-own Breast Milk or Cow's Milk-based Infant Formulas
NCT04059666
Gastrointestinal Microbiome
TERMINATED
NA
Is There a Microbiome Associated With Poor Growth in Preterm Infants?
NCT03761498
Growth Disorders
Growth Failure
Prematurity
ACTIVE_NOT_RECRUITING
A Cohort Study of the Intestinal Microbiota of Premature Infants
NCT03717584
Necrotizing Enterocolitis
Bronchopulmonary Dysplasia
Growth Failure
ACTIVE_NOT_RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this study is to determine: 1) how the gut bacteria of exclusively breastfed infants changes in response to ingesting solid foods; 2) how infant cognition develops in response to ingesting solid foods; and 3) the relationship between infant gut bacteria and infant cognition during the first year of life.
This study is designed to determine how specific complex carbohydrates in commonly used first foods encourage the growth of different bacteria in the infant gut. The two foods used in this study are commercially-available sweet potato (Plum Organics) and pear (Earth's Best). These two foods have been chosen because they differ substantially from each other in their carbohydrate composition. For example, sweet potato is mostly made up of starch which is digestible and pear is made up of other types of sugars found in fruits and vegetables that are not digestible and may have "prebiotic" effects (food for good bacteria in the gut). Thus, the use of these two foods could provide a good contrast for comparing how gut bacteria respond to different carbohydrate compositions during complementary feeding.
This study is designed to determine how specific complex carbohydrates in commonly used first foods encourage the growth of different bacteria in the infant gut. The two foods used in this study are commercially-available sweet potato (Plum Organics) and pear (Earth's Best). These two foods have been chosen because they differ substantially from each other in their carbohydrate composition. For example, sweet potato is mostly made up of starch which is digestible and pear is made up of other types of sugars found in fruits and vegetables that are not digestible and may have "prebiotic" effects (food for good bacteria in the gut). Thus, the use of these two foods could provide a good contrast for comparing how gut bacteria respond to different carbohydrate compositions during complementary feeding.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Microbial Colonization
Infant Development
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
This study is designed as a combined randomized, crossover interventional and observational trial. At the start of the study, infants will enter a 7-day lead-in period to establish gut microbiome and GI tolerability baselines. After the 7-day lead-in period, infants will be randomized into one of two feeding arms comprised of two commercially available baby foods: sweet potato (SP) (Plum Organics, Just Sweet Potato) and pears (P) (Earth's Best, First Pears). The first food, either sweet potato or pears, will be consumed for 7 days followed by a 4-day washout period of exclusive breast milk before initiating the alternate 7-day feeding arm of pears or sweet potato, respectively. The second feeding arm will be followed by an additional 4-day washout period of exclusive breast milk before the introduction of any other solid foods. Once the first month of the study is complete, infants will enter an observational phase for the remainder of the study.
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sweet Potatos
Infants will consume commercially available baby food sweet potato (SP) (Plum Organics, Just Sweet Potato) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of sweet potato to their infant at least three times per day for seven days in a row.
Group Type
EXPERIMENTAL
Sweet Potatos
Intervention Type
OTHER
Plum Organics, Just Sweet Potato
Pears
Infants will consume commercially available baby food pear (P) (Earth's Best, First Pears) for 7 days followed by a 4 day washout period of exclusive breast milk. Participants will be instructed to offer 1-2 tablespoons of pears to their infant at least three times per day for seven days in a row.
Group Type
EXPERIMENTAL
Pears
Intervention Type
OTHER
Earth's Best, First Pears
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sweet Potatos
Plum Organics, Just Sweet Potato
Intervention Type
OTHER
Pears
Earth's Best, First Pears
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women, age 21 to 45 years who have delivered a healthy single infant by vaginal delivery and their infants, age 4 to 7.5 months;
* Infants who are developmentally ready for solids;
* Generally healthy women and infants;
* Mothers who plan to exclusively (without solids or infant formula) breastfeed (at the breast or feed breast milk by bottle) their infants for at least 5 months of age and plan to continue to breastfeed with solids and/or infant formula until 12 months of age;
* Mothers who are willing to either use their own breast pump, or hand-express, or use a manual pump provided by the study to collect milk samples;
* Mothers who are willing to refrain from feeding their infants infant formula, non-study solid foods; probiotic or iron supplements (confounding variables of the intestinal microbiome) before the end of the feeding intervention period;
* Term infants born \>37 weeks gestation;
* Mother-infant pairs who live within a 20-mile radius from University of California, Davis campus in Davis, California (includes Woodland, Vacaville, Dixon and surrounding areas) or within a 20-mile radius of the University of California, Davis Medical Center (UCDMC) (2221 Stockton Blvd, Sacramento, CA 95817).
* Infants who are developmentally ready for solids;
* Generally healthy women and infants;
* Mothers who plan to exclusively (without solids or infant formula) breastfeed (at the breast or feed breast milk by bottle) their infants for at least 5 months of age and plan to continue to breastfeed with solids and/or infant formula until 12 months of age;
* Mothers who are willing to either use their own breast pump, or hand-express, or use a manual pump provided by the study to collect milk samples;
* Mothers who are willing to refrain from feeding their infants infant formula, non-study solid foods; probiotic or iron supplements (confounding variables of the intestinal microbiome) before the end of the feeding intervention period;
* Term infants born \>37 weeks gestation;
* Mother-infant pairs who live within a 20-mile radius from University of California, Davis campus in Davis, California (includes Woodland, Vacaville, Dixon and surrounding areas) or within a 20-mile radius of the University of California, Davis Medical Center (UCDMC) (2221 Stockton Blvd, Sacramento, CA 95817).
Exclusion Criteria
* Infants with any GI tract abnormalities;
* Infants born by cesarean section;
* Family history of immunodeficiency syndrome(s);
* Multiple infants born to one mother at the same time (no twins, triplets, etc.);
* Infants born with medical complications such as: respiratory distress syndrome, birth defects, and infection;
* Mothers diagnosed with any metabolic or endocrine, liver, kidney disease, any autoimmune disease, cirrhosis, hepatitis C, HIV, AIDS, cancer, obesity (pre-pregnancy BMI \>34.9), polycystic ovary syndrome (PCOS), celiac disease, Crohn's disease, heart disease, hyper- or hypothyroidism, hyper- or hypotension (including pre-eclampsia), type 1 or type 2 diabetes.
* Mothers who smoked cigarettes less than one month before becoming pregnant, during pregnancy, and currently or mothers who plan to initiate smoking during the study duration;
* Infants who have taken antibiotics within the past 4 weeks;
* Infants who have taken iron supplements within the past 4 weeks;
* Infants who have consumed infant formula in the past 4 weeks;
* Infants who have consumed infant formula more than 10 days between birth and 4 weeks prior to screening;
* Infants who have consumed any solids;
* Mothers who plan to feed infants solids before 5 months of age;
* Mothers who plan to administer any probiotics to infants throughout the feeding intervention period (first 18 days of the study);
* Infants who have consumed probiotics containing Bifidobacterium within the past 4 weeks or other probiotics within the past 7 days;
* Mothers who live in more than one location (should only live in one house to ensure samples are correctly collected and stored);
* Infants who have hypotonia,
* Infants who have been diagnosed with any medical or nutritional condition that would require iron supplementation.
* Infants who on average pass less than one stool per week.
* Infants born by cesarean section;
* Family history of immunodeficiency syndrome(s);
* Multiple infants born to one mother at the same time (no twins, triplets, etc.);
* Infants born with medical complications such as: respiratory distress syndrome, birth defects, and infection;
* Mothers diagnosed with any metabolic or endocrine, liver, kidney disease, any autoimmune disease, cirrhosis, hepatitis C, HIV, AIDS, cancer, obesity (pre-pregnancy BMI \>34.9), polycystic ovary syndrome (PCOS), celiac disease, Crohn's disease, heart disease, hyper- or hypothyroidism, hyper- or hypotension (including pre-eclampsia), type 1 or type 2 diabetes.
* Mothers who smoked cigarettes less than one month before becoming pregnant, during pregnancy, and currently or mothers who plan to initiate smoking during the study duration;
* Infants who have taken antibiotics within the past 4 weeks;
* Infants who have taken iron supplements within the past 4 weeks;
* Infants who have consumed infant formula in the past 4 weeks;
* Infants who have consumed infant formula more than 10 days between birth and 4 weeks prior to screening;
* Infants who have consumed any solids;
* Mothers who plan to feed infants solids before 5 months of age;
* Mothers who plan to administer any probiotics to infants throughout the feeding intervention period (first 18 days of the study);
* Infants who have consumed probiotics containing Bifidobacterium within the past 4 weeks or other probiotics within the past 7 days;
* Mothers who live in more than one location (should only live in one house to ensure samples are correctly collected and stored);
* Infants who have hypotonia,
* Infants who have been diagnosed with any medical or nutritional condition that would require iron supplementation.
* Infants who on average pass less than one stool per week.
Minimum Eligible Age
21 Years
Maximum Eligible Age
45 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UC Davis Foods for Health Institute
UNKNOWN
Sponsor Role
collaborator
Mengniu Dairy
UNKNOWN
Sponsor Role
collaborator
University of California, Davis
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jennifer Smilowitz, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, Davis
Lisa Oakes, PhD
Role: PRINCIPAL_INVESTIGATOR
University of California, Davis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Davis
Davis, California, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Hoskin-Parr L, Teyhan A, Blocker A, Henderson AJ. Antibiotic exposure in the first two years of life and development of asthma and other allergic diseases by 7.5 yr: a dose-dependent relationship. Pediatr Allergy Immunol. 2013 Dec;24(8):762-71. doi: 10.1111/pai.12153. Epub 2013 Dec 2.
Reference Type
BACKGROUND
Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, Knight R. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11971-5. doi: 10.1073/pnas.1002601107. Epub 2010 Jun 21.
Reference Type
BACKGROUND
Makino H, Kushiro A, Ishikawa E, Muylaert D, Kubota H, Sakai T, Oishi K, Martin R, Ben Amor K, Oozeer R, Knol J, Tanaka R. Transmission of intestinal Bifidobacterium longum subsp. longum strains from mother to infant, determined by multilocus sequencing typing and amplified fragment length polymorphism. Appl Environ Microbiol. 2011 Oct;77(19):6788-93. doi: 10.1128/AEM.05346-11. Epub 2011 Aug 5.
Reference Type
BACKGROUND
Backhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, Li Y, Xia Y, Xie H, Zhong H, Khan MT, Zhang J, Li J, Xiao L, Al-Aama J, Zhang D, Lee YS, Kotowska D, Colding C, Tremaroli V, Yin Y, Bergman S, Xu X, Madsen L, Kristiansen K, Dahlgren J, Wang J. Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life. Cell Host Microbe. 2015 May 13;17(5):690-703. doi: 10.1016/j.chom.2015.04.004.
Reference Type
BACKGROUND
Penders J, Thijs C, Vink C, Stelma FF, Snijders B, Kummeling I, van den Brandt PA, Stobberingh EE. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006 Aug;118(2):511-21. doi: 10.1542/peds.2005-2824.
Reference Type
BACKGROUND
Bezirtzoglou E, Tsiotsias A, Welling GW. Microbiota profile in feces of breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH). Anaerobe. 2011 Dec;17(6):478-82. doi: 10.1016/j.anaerobe.2011.03.009. Epub 2011 Apr 8.
Reference Type
BACKGROUND
Mitsuoka T, Kaneuchi C. Ecology of the bifidobacteria. Am J Clin Nutr. 1977 Nov;30(11):1799-810. doi: 10.1093/ajcn/30.11.1799. No abstract available.
Reference Type
BACKGROUND
Sela DA, Chapman J, Adeuya A, Kim JH, Chen F, Whitehead TR, Lapidus A, Rokhsar DS, Lebrilla CB, German JB, Price NP, Richardson PM, Mills DA. The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18964-9. doi: 10.1073/pnas.0809584105. Epub 2008 Nov 24.
Reference Type
BACKGROUND
Sela DA, Garrido D, Lerno L, Wu S, Tan K, Eom HJ, Joachimiak A, Lebrilla CB, Mills DA. Bifidobacterium longum subsp. infantis ATCC 15697 alpha-fucosidases are active on fucosylated human milk oligosaccharides. Appl Environ Microbiol. 2012 Feb;78(3):795-803. doi: 10.1128/AEM.06762-11. Epub 2011 Dec 2.
Reference Type
BACKGROUND
Sela DA, Li Y, Lerno L, Wu S, Marcobal AM, German JB, Chen X, Lebrilla CB, Mills DA. An infant-associated bacterial commensal utilizes breast milk sialyloligosaccharides. J Biol Chem. 2011 Apr 8;286(14):11909-18. doi: 10.1074/jbc.M110.193359. Epub 2011 Feb 2.
Reference Type
BACKGROUND
Garrido D, Kim JH, German JB, Raybould HE, Mills DA. Oligosaccharide binding proteins from Bifidobacterium longum subsp. infantis reveal a preference for host glycans. PLoS One. 2011 Mar 15;6(3):e17315. doi: 10.1371/journal.pone.0017315.
Reference Type
BACKGROUND
LoCascio RG, Ninonuevo MR, Freeman SL, Sela DA, Grimm R, Lebrilla CB, Mills DA, German JB. Glycoprofiling of bifidobacterial consumption of human milk oligosaccharides demonstrates strain specific, preferential consumption of small chain glycans secreted in early human lactation. J Agric Food Chem. 2007 Oct 31;55(22):8914-9. doi: 10.1021/jf0710480. Epub 2007 Oct 5.
Reference Type
BACKGROUND
Krebs NF, Sherlock LG, Westcott J, Culbertson D, Hambidge KM, Feazel LM, Robertson CE, Frank DN. Effects of different complementary feeding regimens on iron status and enteric microbiota in breastfed infants. J Pediatr. 2013 Aug;163(2):416-23. doi: 10.1016/j.jpeds.2013.01.024. Epub 2013 Feb 26.
Reference Type
BACKGROUND
Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Dore J; MetaHIT Consortium; Antolin M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Merieux A, Melo Minardi R, M'rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. Enterotypes of the human gut microbiome. Nature. 2011 May 12;473(7346):174-80. doi: 10.1038/nature09944. Epub 2011 Apr 20.
Reference Type
BACKGROUND
Davis LM, Martinez I, Walter J, Hutkins R. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol. 2010 Dec 15;144(2):285-92. doi: 10.1016/j.ijfoodmicro.2010.10.007. Epub 2010 Oct 14.
Reference Type
BACKGROUND
Faith JJ, Guruge JL, Charbonneau M, Subramanian S, Seedorf H, Goodman AL, Clemente JC, Knight R, Heath AC, Leibel RL, Rosenbaum M, Gordon JI. The long-term stability of the human gut microbiota. Science. 2013 Jul 5;341(6141):1237439. doi: 10.1126/science.1237439.
Reference Type
BACKGROUND
Martinez I, Muller CE, Walter J. Long-term temporal analysis of the human fecal microbiota revealed a stable core of dominant bacterial species. PLoS One. 2013 Jul 16;8(7):e69621. doi: 10.1371/journal.pone.0069621. Print 2013.
Reference Type
BACKGROUND
de Theije CG, Wopereis H, Ramadan M, van Eijndthoven T, Lambert J, Knol J, Garssen J, Kraneveld AD, Oozeer R. Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav Immun. 2014 Mar;37:197-206. doi: 10.1016/j.bbi.2013.12.005. Epub 2013 Dec 11.
Reference Type
BACKGROUND
Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013 May;36(5):305-12. doi: 10.1016/j.tins.2013.01.005. Epub 2013 Feb 4.
Reference Type
BACKGROUND
Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol. 2004 Nov;70(11):6459-65. doi: 10.1128/AEM.70.11.6459-6465.2004.
Reference Type
BACKGROUND
Wang L, Christophersen CT, Sorich MJ, Gerber JP, Angley MT, Conlon MA. Low relative abundances of the mucolytic bacterium Akkermansia muciniphila and Bifidobacterium spp. in feces of children with autism. Appl Environ Microbiol. 2011 Sep;77(18):6718-21. doi: 10.1128/AEM.05212-11. Epub 2011 Jul 22.
Reference Type
BACKGROUND
Diaz Heijtz R, Wang S, Anuar F, Qian Y, Bjorkholm B, Samuelsson A, Hibberd ML, Forssberg H, Pettersson S. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):3047-52. doi: 10.1073/pnas.1010529108. Epub 2011 Jan 31.
Reference Type
BACKGROUND
Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol. 2012 Nov;10(11):735-42. doi: 10.1038/nrmicro2876. Epub 2012 Sep 24.
Reference Type
BACKGROUND
Borre YE, O'Keeffe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental windows: implications for brain disorders. Trends Mol Med. 2014 Sep;20(9):509-18. doi: 10.1016/j.molmed.2014.05.002. Epub 2014 Jun 20.
Reference Type
BACKGROUND
Totten SM, Zivkovic AM, Wu S, Ngyuen U, Freeman SL, Ruhaak LR, Darboe MK, German JB, Prentice AM, Lebrilla CB. Comprehensive profiles of human milk oligosaccharides yield highly sensitive and specific markers for determining secretor status in lactating mothers. J Proteome Res. 2012 Dec 7;11(12):6124-33. doi: 10.1021/pr300769g. Epub 2012 Nov 19.
Reference Type
BACKGROUND
Tao N, DePeters EJ, Freeman S, German JB, Grimm R, Lebrilla CB. Bovine milk glycome. J Dairy Sci. 2008 Oct;91(10):3768-78. doi: 10.3168/jds.2008-1305.
Reference Type
BACKGROUND
Tao N, DePeters EJ, German JB, Grimm R, Lebrilla CB. Variations in bovine milk oligosaccharides during early and middle lactation stages analyzed by high-performance liquid chromatography-chip/mass spectrometry. J Dairy Sci. 2009 Jul;92(7):2991-3001. doi: 10.3168/jds.2008-1642.
Reference Type
BACKGROUND
Vatanen T, Kostic AD, d'Hennezel E, Siljander H, Franzosa EA, Yassour M, Kolde R, Vlamakis H, Arthur TD, Hamalainen AM, Peet A, Tillmann V, Uibo R, Mokurov S, Dorshakova N, Ilonen J, Virtanen SM, Szabo SJ, Porter JA, Lahdesmaki H, Huttenhower C, Gevers D, Cullen TW, Knip M; DIABIMMUNE Study Group; Xavier RJ. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell. 2016 May 5;165(4):842-53. doi: 10.1016/j.cell.2016.04.007. Epub 2016 Apr 28.
Reference Type
BACKGROUND
Rotmistrovsky, K. and R. Agarwala, BMTagger: Best Match Tagger for removing human reads from metagenomics datasets. 2011.
Reference Type
BACKGROUND
Schmieder R, Edwards R. Fast identification and removal of sequence contamination from genomic and metagenomic datasets. PLoS One. 2011 Mar 9;6(3):e17288. doi: 10.1371/journal.pone.0017288.
Reference Type
BACKGROUND
Ames SK, Gardner SN, Marti JM, Slezak TR, Gokhale MB, Allen JE. Using populations of human and microbial genomes for organism detection in metagenomes. Genome Res. 2015 Jul;25(7):1056-67. doi: 10.1101/gr.184879.114. Epub 2015 Apr 29.
Reference Type
BACKGROUND
Kleinman RE. American Academy of Pediatrics recommendations for complementary feeding. Pediatrics. 2000 Nov;106(5):1274. No abstract available.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://studypages.com/s/an-examination-of-infants-microbiome-nutrition-and-development-study-123299/
Learn more or sign up for the study here!
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
919505
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Prebiotic in Preterm Infants
NCT03306316
COMPLETED
NA
The Milk, Growth and Microbiota Study
NCT03220282
SUSPENDED
NA
Human-derived Human Milk Fortifiers (H2MF), Gut Microbiota and Oxidative Stress in Premature Infants
NCT03214822
COMPLETED
NA
Metagenomic Analysis of Gut Microbiome in Preterm
NCT03235635
UNKNOWN
The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies
NCT06072976
UNKNOWN
NA
Effects of Complementary Feeding on Infant Growth and Gut Health
NCT05012930
ACTIVE_NOT_RECRUITING
NA
The Influence of Infant Feeding Type on Preterm Infant's Intestinal Microbiome
NCT04972214
UNKNOWN
Evaluation of Safety, Tolerance and Effects on the Intestinal Flora of a New Fermented Milk for Preterm Infants
NCT00711633
COMPLETED
NA
Early Iron Exposure on the Gut Microbiota in Young Infants
NCT03828708
UNKNOWN
NA
Exploratory/Proof of Principle Microbiota Study
NCT02500563
COMPLETED
NA
Study to Evaluate the Effects of a Formula on the Gut Health of Healthy Chinese Infants and Young Children
NCT04864665
COMPLETED
NA
Impact of a Fermented Infant Formula in Weaning Babies
NCT00858026
COMPLETED
NA
The Role of Human Milk Oligosaccharides and Microbiomes on Infantile Colic and Atopic Dermatitis in Term Infants
NCT05992493
ACTIVE_NOT_RECRUITING
Shaping Microbiome in the First 1,000 Days of Life
NCT04122612
COMPLETED
Parental Notions and Clinical Experiences About Child's Gut Comfort, Overall Satisfaction and Sense of Well-being When Consuming a New Toddler Milk
NCT04768933
COMPLETED
NA
Oral Administration of Colostrum to Premature Babies: Impact on the Oral Microbiota
NCT02306980
COMPLETED
NA
Evaluation of Preterm Infants Fed Post-Discharge Preterm Infant Formula
NCT03991949
COMPLETED
NA
The Impact of a Prebiotics and Lactoferrin Containing Infant Formula on Stool Characteristics in Healthy Term Infants
NCT02363582
COMPLETED
NA
Gut Microbiota of Preterm Infants and Full-term Infants at Early Life
NCT03373721
RECRUITING
Sweet Cheeks: How Early Nutrition Affects Oral Microbiota Populations and Disease Incidence
NCT01836952
COMPLETED
Association of Gut Microbiome With Neonatal Complications and Neurodevelopment in Preterm Infants
NCT03841994
COMPLETED
How Infant Diets Would Affect Growth in Early Childhood
NCT02440503
COMPLETED
Feeding Bovine Colostrum to Preterm Infants
NCT02054091
COMPLETED
NA
Gut Bacteria and Brain of the Baby
NCT04432636
RECRUITING
NA
Neonatal Microbiome Validity Study
NCT02655250
COMPLETED